Literature DB >> 32724039

Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas.

Alexander Pemov1, Ramita Dewan2,3, Nancy F Hansen4, Settara C Chandrasekharappa4, Abhik Ray-Chaudhury2, Kristine Jones5, Wen Luo5, John D Heiss2, James C Mullikin4,6, Prashant Chittiboina2, Douglas R Stewart7, Ashok R Asthagiri8,9.   

Abstract

Neurofibromatosis type 2 (NF2) is an autosomal dominant Mendelian tumor predisposition disorder caused by germline pathogenic variants in the tumor suppressor NF2. Meningiomas are the second most common neoplasm in NF2, often occurring in multiple intracranial and spinal locations within the same patient. In this prospective longitudinal study, we assessed volumes and growth rates of ten spinal and ten cranial benign meningiomas in seven NF2 patients that concluded with surgical resection and performed whole-exome sequencing and copy-number variant (CNV) analysis of the tumors. Our comparison of the volume and the growth rate of NF2-associated spinal and cranial meningiomas point to the differences in timing of tumor initiation and/or to the differences in tumor progression (e.g., non-linear, saltatory growth) at these two anatomical locations. Genomic investigation of these tumors revealed that somatic inactivation of NF2 is the principal and perhaps the only driver of tumor initiation; and that tumor progression likely occurs via accumulation of CNVs, rather than point mutations. Results of this study contribute to a better understanding of NF2-associated meningiomas clinical behavior and their genetic underpinnings.

Entities:  

Mesh:

Year:  2020        PMID: 32724039      PMCID: PMC7387487          DOI: 10.1038/s41598-020-69074-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  46 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

4.  Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.

Authors:  Stéphane Goutagny; Alpha Boubacar Bah; Dominique Henin; Béatrice Parfait; Alexis Bozorg Grayeli; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

5.  Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought.

Authors:  D Gareth R Evans; Anthony Moran; Andrew King; S Saeed; Nihal Gurusinghe; Richard Ramsden
Journal:  Otol Neurotol       Date:  2005-01       Impact factor: 2.311

6.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

7.  Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

Authors:  D G Evans; E Howard; C Giblin; T Clancy; H Spencer; S M Huson; F Lalloo
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

8.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

9.  Long-term outcomes after radiosurgery for acoustic neuromas.

Authors:  D Kondziolka; L D Lunsford; M R McLaughlin; J C Flickinger
Journal:  N Engl J Med       Date:  1998-11-12       Impact factor: 91.245

10.  Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity.

Authors:  D M Parry; R Eldridge; M I Kaiser-Kupfer; E A Bouzas; A Pikus; N Patronas
Journal:  Am J Med Genet       Date:  1994-10-01
View more
  2 in total

Review 1.  Synthesizing Molecular and Immune Characteristics to Move Beyond WHO Grade in Meningiomas: A Focused Review.

Authors:  Nivedha V Kannapadi; Pavan P Shah; Dimitrios Mathios; Christopher M Jackson
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

Review 2.  Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.

Authors:  Suha Bachir; Sanjit Shah; Scott Shapiro; Abigail Koehler; Abdelkader Mahammedi; Ravi N Samy; Mario Zuccarello; Elizabeth Schorry; Soma Sengupta
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.